Please provide your email address to receive an email when new articles are posted on . Many patients I see in practice have some form of presbyopia, whether in an early phase or more severe. About 80 ...

Please provide your email address to receive an email when new articles are posted on . Presbyopia is a ubiquitous and progressive symptom of aging that was previously only treatable with reading ...

Scientists have developed new eye drops that could help with presbyopia. Ekaterina Vasileva-Bagler/Getty Images For this study, researchers recruited 766 participants diagnosed with presbyopia.

The MarketWatch News Department was not involved in the creation of this content. The launch of emerging therapies, such as LNZ100 by Lenz Therapeutics, Phentolamine Ophthalmic Solution 0.75% by ...

- Investigational, novel eye drop candidate was assigned PDUFA goal date of October 22, 2023 PONTE VEDRA, Fla., Feb. 21, 2023 /PRNewswire/ -- Orasis Pharmaceuticals, an emerging ophthalmic ...

The FDA approved pilocarpine hydrochloride ophthalmic solution (Qlosi) for adults with presbyopia, according to a statement from Orasis Pharmaceuticals. The approval allows for daily or as-needed use, ...

VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia, a condition impacting approximately 128 million adults in the United States First once ...

Welcome to the health and wellness podcast. In this episode, we are joined by Irene Gitonga, an optometrist, to discuss the causes, symptoms, and treatment of presbyopia. Tune in to listen.

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal ...

The market for presbyopia eye drops, which can sharpen vision with just one drop, is expected to officially open in South Korea. Kwangdong Pharmaceutical announced on the 13th that YUVEZZI, a ...

Detailed price information for Opus Genetics Inc (IRD-Q) from The Globe and Mail including charting and trades.